Key terms
About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest JNJ news
Yesterday
5:20am ET
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ) and Intra-Cellular Therapies (ITCI)
Yesterday
3:59am ET
RBC Capital Reaffirms Their Buy Rating on Johnson & Johnson (JNJ)
Apr 16
1:35pm ET
Steady Performance and Aligned Guidance Justify Hold Rating for Johnson & Johnson
Apr 16
1:30pm ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cullinan Management (CGEM), Johnson & Johnson (JNJ) and UnitedHealth (UNH)
Apr 16
11:49am ET
J&J report ‘not alarming’ for Legend Biotech, says H.C. Wainwright
Apr 16
9:30am ET
Johnson & Johnson says no change to M&A strategy
Apr 16
8:58am ET
Johnson & Johnson says ‘off to solid financial start’ in 2024
Apr 16
8:15am ET
Balancing Act: Hold Rating on Johnson & Johnson Amid Steady Growth and Legal Challenges
Apr 16
7:29am ET
JNJ Earnings: Johnson & Johnson’s Q1 Earnings Beat Estimates
Apr 16
7:05am ET
Options Volatility and Implied Earnings Moves Today, April 16, 2024
Apr 16
6:43am ET
Johnson & Johnson sees ‘slightly stronger’ sales in Innovative Medicine in 1H24
Apr 16
6:25am ET
Johnson & Johnson raises quarterly dividend 4.2% to $1.24 from $1.19 per share
Apr 16
6:25am ET
Johnson & Johnson raises quarterly dividend 4.2% to $1.24 from $1.19 per share
Apr 16
6:23am ET
Johnson & Johnson revises FY24 adjusted EPS to $10.60-$10.75 from $10.55-$10.75
Apr 16
6:20am ET
Johnson & Johnson reports Q1 adjusted EPS $2.71, consensus $2.64
Apr 16
5:32am ET
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Amylyx Pharmaceuticals Inc (AMLX) and Rhythm Pharmaceuticals (RYTM)
Apr 15
8:25pm ET
Notable companies reporting before tomorrow’s open
Apr 15
12:57pm ET
Notable companies reporting before tomorrow’s open
Apr 15
12:57pm ET
Notable companies reporting before tomorrow’s open
Apr 15
7:45am ET
Cantor Fitzgerald Keeps Their Buy Rating on Johnson & Johnson (JNJ)
Apr 15
7:00am ET
Options Volatility and Implied Earnings Moves This Week, April 15 – April 19, 2024
Apr 15
6:28am ET
Mind Medicine initiated with an Outperform at Leerink
Apr 15
6:08am ET
Integer upgraded to Buy from Neutral at BofA
Apr 12
1:37pm ET
Buy/Sell: Wall Street’s top 10 stock calls this week
Apr 11
9:40am ET
DoorDash upgraded, Airbnb downgraded: Wall Street’s top analyst calls
Apr 11
8:16am ET
Rallybio price target lowered to $11 from $13 at Wedbush
Apr 10
4:22pm ET
Kenvue initiated with an Underperform at Bernstein
Apr 10
4:03pm ET
Rallybio to partner with J&J on soultions to reduce risk of FNAIT
Apr 08
9:44am ET
Ulta upgraded, Skyworks downgraded: Wall Street’s top analyst calls
Apr 08
7:37am ET
ShockWave Medical downgraded to Hold from Buy at Needham
Apr 08
7:04am ET
Johnson & Johnson announces presentation of findings on XARELTO
No recent press releases are available for JNJ
JNJ Financials
Key terms
Ad Feedback
JNJ Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
JNJ Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
